Myovant Sciences to Present at the 40th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Myovant Sciences (NYSE: MYOV) will have CEO David Marek present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 3:00 p.m. ET. This event invites both investors and the public to access the presentation via Myovant's website. Myovant focuses on innovative healthcare solutions for women's and men's health, with notable achievements including two FDA approvals for advanced prostate cancer and heavy menstrual bleeding. The company is also pursuing additional regulatory submissions and clinical trials.

BASEL, Switzerland, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that David Marek, Chief Executive Officer of Myovant Sciences, Inc., will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 3:00 p.m. Eastern Time.

Investors and the general public are invited to listen to the presentation, which will be accessible on the Events page under the Investors & Media section of the Myovant website at www.myovant.com.

About Myovant Sciences 
Myovant Sciences aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Founded in 2016, Myovant has executed five successful Phase 3 clinical trials across oncology and women’s health leading to two regulatory approvals by the U.S. Food and Drug Administration for men with advanced prostate cancer and women with heavy menstrual bleeding associated with uterine fibroids, respectively, as well as a European Commission approval for women with symptomatic uterine fibroids. Additionally, Myovant has two regulatory submissions under review, a Marketing Authorization Application in advanced prostate cancer and a supplemental New Drug Application in endometriosis-associated pain. Myovant is conducting a Phase 3 study to evaluate the prevention of pregnancy in women with uterine fibroids or endometriosis. Myovant is also developing MVT-602, an investigational oligopeptide kisspeptin-1 receptor agonist, which has completed a Phase 2a study for female infertility as part of assisted reproduction. Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is Myovant’s majority shareholder. For more information, please visit www.myovant.com. Follow @Myovant on Twitter and LinkedIn.

Investor Contact:
Ryan Crowe
Vice President, Investor Relations
Myovant Sciences, Inc.
+1 (650) 781-9106
investors@myovant.com

Media Contact:
Albert Liao 
Director, Corporate Communications
Myovant Sciences, Inc.
+1 (650) 410-3055
media@myovant.com

FAQ

When is Myovant Sciences' presentation at the J.P. Morgan Healthcare Conference?

Myovant Sciences' presentation is scheduled for January 12, 2022, at 3:00 p.m. Eastern Time.

Who is presenting for Myovant Sciences at the J.P. Morgan Healthcare Conference?

David Marek, Chief Executive Officer of Myovant Sciences, will be presenting.

How can I listen to Myovant Sciences' presentation?

The presentation will be accessible on the Events page under the Investors & Media section of Myovant's website.

What are Myovant Sciences' recent achievements?

Myovant has received FDA approvals for advanced prostate cancer and heavy menstrual bleeding, and is pursuing more regulatory submissions.

What areas is Myovant Sciences focused on?

Myovant Sciences focuses on redefining care for women's and men's health through innovative treatments and clinical trials.